According to the Centers for Disease Control and Prevention (CDC), osteoarthritis (OA) impacts more than 30 million Americans, leading to pain and stiffness of the joints that can make everyday activities and tasks difficult to accomplish. Knee OA is one of the most common and challenging forms of this condition. 75% of knee OA patients experience movement limitations and 97% of individuals report that their daily lives are negatively affected by this condition. While there are a variety of treatment options available, including over-the-counter (OTC) medications, topical creams, opioids, ice, and elevation, these options may not be sustainable for long-term relief. Recognizing that there is no one-size-fits-all approach to pain management is important to increase awareness of innovative treatment options. This can help those suffering from knee OA receive the sustained relief they need to live comfortably.
In my role as an orthopedic surgeon, I’m committed to providing my patients with consistent, long-lasting relief that minimizes the need for frequent clinic visits while ensuring that they can return to their daily activities with ease. That’s why I’ve incorporated ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) into my practice. ZILRETTA is the first FDA-approved knee OA treatment using extended-release microsphere technology. Unlike conventional knee pain injections and opioids that target pain throughout the body, ZILRETTA is administered directly into the knee, where its microspheres remain, to deliver continuous pain relief for up to three months.
This innovative treatment captured my attention due to its potential to offer a season of pain relief for my patients. As a non-opioid option, ZILRETTA provides safe and effective pain management while mitigating the risks associated with opioids such as dependence and addiction. This treatment option is also particularly valuable for patients who are not yet ready for knee replacement surgery, or who may not be candidates for surgery, but are still seeking lasting comfort*.
With 15 million Americans experiencing symptomatic OA of the knee, it’s evident that this condition is a widespread issue that demands attention. If you find yourself among the millions who endure the challenges of chronic OA knee pain, I recommend discussing ZILRETTA with your healthcare provider. This injectable, non-opioid pain treatment has the potential to offer relief from the daily struggles associated with OA knee pain. Reach out to your doctor and ask how ZILRETTA can bring lasting comfort and relief to your life.
For more information, please visit https://zilretta.com/important-risk-information/.
This article is sponsored by Pacira BioSciences, Inc., manufacturer of ZILRETTA
Dr. Palumbo is a paid consultant of Pacira BioSciences, Inc.
*This is based on Dr. Palumbo’s own experience using ZILRETTA. Results may vary.
ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) is an extended-release corticosteroid approved to manage osteoarthritis knee pain. The benefits and risks of repeat injections have not been demonstrated.
You should not receive a ZILRETTA injection if you are allergic to corticosteroids, triamcinolone acetonide, or any other component of the product.
Important Safety Information
Possible side effects:
· Rare serious allergic reactions
· Effects in the injected knee such as infection (with pain, swelling and restricted motion) or joint damage
· Increased chance of getting an infection, and a decreased ability to fight an infection
· Effects on hormone production. These effects can be reversible
· Elevated blood pressure, sodium and water retention, and potassium loss
· Intestinal perforation if you have certain gastrointestinal disorders
· Weakening of bones
· Changes in behavior or mood disturbances
· Increased pressure inside the eye
In multiple clinical trials, the most common side effects seen in people taking ZILRETTA were joint pain, headache, joint swelling, back pain, sore throat and runny nose, upper respiratory tract infection, and bruising.
Tell your doctor about all of the medications you are taking (including both prescription and over-the-counter medicines) and about any medical conditions, especially if you have high blood pressure, heart disease, ulcers, diverticulitis or other gastrointestinal disorders, kidney problems, diabetes, glaucoma, behavior or mood disorders, and/or infections.
Contact your doctor if you develop a fever or other signs of infection, have an increase in pain along with swelling of the injected knee, restriction of joint motion, or a general feeling of discomfort. Contact your doctor immediately if you are exposed to chicken pox or measles, or for any new or worsening changes in behavior or mood.
These are not all of the possible side effects with ZILRETTA or corticosteroid medications. Please see the full Prescribing Information at www.ZILRETTALabel.com/PI.pdf. Always contact your doctor if you have questions or experience any side effects.
To report SUSPECTED ADVERSE REACTIONS, contact Pacira Pharmaceuticals, Inc. at 1-844-353-9466 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.